OAS2 Antibody (G-9): sc-271117

OAS2 Antibody (G-9) is a mouse monoclonal IgG2b kappa light chain antibody that detects OAS2 protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry, and enzyme-linked immunosorbent assay (ELISA). OAS2 (G-9) antibody is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. The 2′-5′-oligoadenylate synthetase (OAS) family, which includes OAS1, OAS2, OAS3, and OASL, is crucial for cellular response to viral infections, as these proteins are induced by interferons and catalyze the conversion of ATP into 2′-5′-linked oligomers of adenosine in the presence of double-stranded RNA and magnesium ions. OAS2, characterized as the "medium form" within this family, possesses a unique structure comprising two OAS1-homologous domains linked by a proline-rich region, and functions effectively as a dimer. This structural configuration enables proper interaction with substrates and regulatory ions for enzymatic activity. The OAS family plays a significant role in inhibiting cellular protein synthesis, contributing to host defense against viral infections. Abnormal OAS2 expression levels have been associated with exacerbations in patients with lupus, highlighting OAS2′s potential as a biomarker for disease activity.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

OAS2 Antibody (G-9) References:

1. Inhibition of 2'-5' oligoadenylate synthetase by divalent metal ions.  |  Hartmann, R., et al. 2001. FEBS Lett. 507: 54-8. PMID: 11682059
2. Genomic structure of the mouse 2',5'-oligoadenylate synthetase gene family.  |  Kakuta, S., et al. 2002. J Interferon Cytokine Res. 22: 981-93. PMID: 12396720
3. Characterization of the 2'-5'-oligoadenylate synthetase ubiquitin-like family.  |  Eskildsen, S., et al. 2003. Nucleic Acids Res. 31: 3166-73. PMID: 12799444
4. Anti-viral actions and viral dynamics in the early phase of three different regimens of interferon treatment for chronic hepatitis C: differences between the twice-daily administration of interferon-beta treatment and the combination therapy with interferon-alpha plus ribavirin.  |  Nakajima, H., et al. 2003. Acta Med Okayama. 57: 217-25. PMID: 14679399
5. Three-dimensional models of human 2'-5' oligoadenylate synthetases: a new computational method for reconstructing an enzyme assembly.  |  Torshin, IY. 2005. Med Sci Monit. 11: BR235-47. PMID: 15990685
6. Type 1 diabetes and the OAS gene cluster: association with splicing polymorphism or haplotype?  |  Tessier, MC., et al. 2006. J Med Genet. 43: 129-32. PMID: 16014697
7. The mammalian 2'-5' oligoadenylate synthetase gene family: evidence for concerted evolution of paralogous Oas1 genes in Rodentia and Artiodactyla.  |  Perelygin, AA., et al. 2006. J Mol Evol. 63: 562-76. PMID: 17024523
8. 2', 5'-Oligoadenylate Synthetase 2 (OAS2) Inhibits Zika Virus Replication through Activation of Type Ι IFN Signaling Pathway.  |  Liao, X., et al. 2020. Viruses. 12: PMID: 32276512
9. Prognostic characterization of OAS1/OAS2/OAS3/OASL in breast cancer.  |  Zhang, Y. and Yu, C. 2020. BMC Cancer. 20: 575. PMID: 32560641
10. AT1R autoantibody promotes phenotypic transition of smooth muscle cells by activating AT1R-OAS2.  |  Zhang, X., et al. 2024. Biochem Pharmacol. 219: 115977. PMID: 38092283
11. Genetic variants of LRRC8C, OAS2, and CCL25 in the T cell exhaustion-related genes are associated with non-small cell lung cancer survival.  |  Lu, G., et al. 2024. Front Immunol. 15: 1455927. PMID: 39416786
12. Induction of 2.5 OAS gene expression and activity is not sufficient for IFN-gamma-induced neuroblastoma cell differentiation.  |  Corrias, MV., et al. 1995. Int J Cancer. 62: 223-9. PMID: 7622300

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-OAS2 Antibody (G-9) has 10 citations in a variety of scientific publications.

Primary antibodies like Anti-OAS2 Antibody (G-9) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

OAS2 Antibody (G-9) Specifications

Alternate Product Name: OAS2

Product Clone Name: G-9

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG_2b kappa light chain

Amino Acids: 706-735

Epitope Target: OAS2

Epitope Species: mouse

Product Reactivity/Detection: OAS2

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 200 µg IgG_2b kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 10 citations in various scientific publications

Available Conjugates/Forms for OAS2 Antibody (G-9): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, P: Blocking Peptide, PE: Phycoerythrin, X: TransCruz Reagent